Longeveron Announces Closing of $5.2 Million Public Offering tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
MIAMI, April 11, 2024 (GLOBE NEWSWIRE) Longeveron Inc. (NASDAQ:LGVN) ("Longeveron" or the "Company"), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic
Industry veteran with over 40 years of experience in finance, investment management, and investment bankingWESTLAKE VILLAGE, Calif., April 10, 2024 Arcutis Biotherapeutics, Inc. , a.
MIAMI, April 08, 2024 (GLOBE NEWSWIRE) Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as